Analyst Price Targets — CLBT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 14, 2026 1:25 pm | Rudy Kessinger | D.A. Davidson | $15.00 | $10.95 | StreetInsider | Cellebrite (CLBT) PT Lowered to $15 at DA Davidson Following Q2 Miss |
| August 14, 2026 12:48 pm | — | Lake Street | $15.00 | $10.91 | TheFly | Cellebrite price target lowered to $15 from $21 at Lake Street |
| August 14, 2026 12:30 pm | — | Deutsche Bank | $14.00 | $10.89 | TheFly | Cellebrite price target lowered to $14 from $20 at Deutsche Bank |
| August 14, 2026 11:04 am | Mike Cikos | Needham | $12.50 | $10.80 | StreetInsider | Cellebrite (CLBT) PT Lowered to $12.50 at Needham |
| August 6, 2026 1:20 pm | Rudy Kessinger | D.A. Davidson | $22.00 | $15.53 | TheFly | Cellebrite price target raised to $22 from $20 at DA Davidson |
| May 26, 2026 8:28 pm | — | D.A. Davidson | $20.00 | $12.89 | TheFly | Cellebrite initiated with a Buy at DA Davidson |
| May 15, 2026 1:44 pm | — | Needham | $15.00 | $13.03 | TheFly | Cellebrite price target lowered to $15 from $18 at Needham |
| February 12, 2026 1:39 pm | Eric Martinuzzi | Lake Street | $21.00 | $13.86 | TheFly | Cellebrite price target lowered to $21 from $23 at Lake Street |
| February 12, 2026 1:38 pm | — | UBS | $23.00 | $13.85 | TheFly | Cellebrite price target lowered to $23 from $25 at TD Cowen |
| February 12, 2026 12:18 pm | — | Needham | $18.00 | $14.26 | TheFly | Cellebrite price target lowered to $18 from $24 at Needham |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for CLBT

New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ: CLBT).

Cellebrite offers ~90% recurring revenue and 117% net retention, anchored by mobile forensics leadership and new growth levers. Cellebrite is rated 'Buy' at ~$12, with a Fair Value estimate of $17.3, reflecting ~44% potential upside and a strong GARP profile. I see a narrow moat based on their leadership in mobile forensics, robust rule of X score, and cross-selling opportunities.

/PRNewswire/ -- Cellebrite (Nasdaq: CLBT), leader mondial des solutions d'investigation et de renseignement numériques basées sur l'IA pour les secteurs

/PRNewswire/ -- Cellebrite DI Ltd. (Nasdaq: CLBT), líder mundial en soluciones de inteligencia e investigación digital basadas en IA para los sectores público

Independent assessment gives Australian law enforcement, defense and national security agencies a platform for collaborating and managing digital evidence in the cloud quickly and securely TYSONS CORNER, Va. and PETAH TIKVA, Israel, Sept.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLBT.
U.S. House Trading
No House trades found for CLBT.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
